ATAI Life Sciences and the psychedelic drug sector received a boost following finalized FDA guidance. This regulatory shift aims to reduce uncertainty and risk for developers in the industry.
Investment bank Jefferies reports the guidance signals a more supportive regulatory environment. The FDA also scheduled a public hearing on the matter for September.
The finalized framework offers a flexible approach to nonclinical studies. It also provides updated recommendations for clinical trial designs.
The development follows a recent agreement between the Department of Health and Human Services and the Veterans Administration. Both agencies will collaborate to advance psychedelic medications for veterans.